Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series
Montanari F, Bhagat G, Seshan V, Clark-Garvey S, Zain J, Diefenbach C, McCormick E, Conroy M, Crook M, Alobeid B, O'Connor O. Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series. Blood 2010, 116: 4151. DOI: 10.1182/blood.v116.21.4151.4151.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderECOG score 0Epstein-Barr virusEpstein-Barr virus statusECOG scoreP-PTLDAdult patientsPediatric patientsScore 0Immunosuppression taperingM-PTLDRituximab groupMedian OSEarly lesionsLymphoproliferative disordersAdvanced stage III or IVPTLD subtypesIntermediate-low-risk groupSpectrum of lymphoproliferative disordersMedian OS of patientsIntermediate-high risk groupHematopoietic stem cell transplantationWorld Health Organization classification systemStage III or IVPopulation of adult patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply